Oxford BioMedica (LON:OXB) Earns “Buy” Rating from Liberum Capital

Liberum Capital reissued their buy rating on shares of Oxford BioMedica (LON:OXB) in a report issued on Tuesday, ThisIsMoney.Co.Uk reports.

OXB has been the topic of several other reports. Peel Hunt reiterated a buy rating on shares of Oxford BioMedica in a report on Monday, September 2nd. Peel Hunt reiterated a buy rating on shares of Oxford BioMedica in a report on Wednesday, June 26th.

Shares of LON:OXB opened at GBX 548 ($7.16) on Tuesday. The company has a market capitalization of $426.07 million and a price-to-earnings ratio of -47.24. Oxford BioMedica has a 12 month low of GBX 461.50 ($6.03) and a 12 month high of GBX 793 ($10.36). The firm’s 50-day moving average is GBX 548.55 and its 200 day moving average is GBX 659.03. The company has a current ratio of 2.21, a quick ratio of 1.80 and a debt-to-equity ratio of 10.55.

In related news, insider Martin Diggle bought 17,953 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were acquired at an average cost of GBX 577 ($7.54) per share, for a total transaction of £103,588.81 ($135,357.13). Also, insider Lorenzo Tallarigo bought 427 shares of the company’s stock in a transaction on Friday, August 23rd. The stock was bought at an average price of GBX 626 ($8.18) per share, for a total transaction of £2,673.02 ($3,492.77). Insiders have purchased a total of 18,862 shares of company stock worth $10,893,211 over the last quarter.

Oxford BioMedica Company Profile

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

See Also: Google Finance Portfolio Workaround

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.